Tabarak Qureshi, MD
Pulmonary Disease · Altamonte Springs, FLNPI 1962674549
Payments from drug & device makers
Across 495 payments — averaging $543.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$105K
- Regeneron Healthcare Solutions, Inc.$59K
- AstraZeneca$48K
- Inspire Medical Systems, Inc.$26K
- Paratek Pharmaceuticals, Inc.$24K
- Novartis$1K
- plus $6K from 30 others
What the payments were for
- Consulting fees$11,1385%
- Speaking & faculty fees$174,62985%
- Travel & lodging$10,8915%
- Food & beverage$9,2264%
- Education$160%
- Gifts$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 93 | $105,125 |
| Regeneron Healthcare Solutions, Inc. | 67 | $59,429 |
| AstraZeneca | 96 | $47,832 |
| Inspire Medical Systems, Inc. | 17 | $26,022 |
| Paratek Pharmaceuticals, Inc. | 8 | $23,747 |
| Novartis | 10 | $1,333 |
| Johnson & Johnson | 9 | $962 |
| Actelion Pharmaceuticals US, Inc. | 45 | $854 |
| Pulmonx Corporation | 5 | $805 |
| GSK | 20 | $349 |
| Boehringer Ingelheim | 17 | $278 |
| Sunovion Pharmaceuticals Inc. | 15 | $263 |
| Harmony Biosciences LLC | 9 | $244 |
| Philips North America LLC | 8 | $155 |
| Genentech USA, Inc. | 3 | $149 |
| United Therapeutics Corporation | 4 | $136 |
| Gilead | 7 | $127 |
| Bayer | 6 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $122 |
| UCB, Inc. | 7 | $118 |
| Veran Medical Technologies, Inc. | 3 | $116 |
| Mylan Specialty L.p. | 6 | $115 |
| Jazz Pharmaceuticals Inc. | 5 | $106 |
| Sanofi-aventis U.S. LLC | 2 | $100 |
| Insmed, Inc. | 5 | $81 |
| Mallinckrodt Hospital Products Inc. | 5 | $81 |
| Grifols USA, LLC | 4 | $75 |
| Amgen | 2 | $49 |
| AbbVie | 2 | $31 |
| Portola Pharmaceuticals, LLC | 2 | $28 |
| Fisher & Paykel Healthcare Inc | 2 | $28 |
| Advanced Respiratory, Inc | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Covis Pharma GmbH | 1 | $25 |
| Baxter Healthcare | 1 | $24 |
| Shire North American Group Inc | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$150,157
- BREZTRI$22,636
- FASENRA$15,400
- BREZTRI AEROSPHERE$7,398
- TAGRISSO$1,269
- Monarch Platform$877
- Pulmonx Endobronchial Valve EBV$742
- Inspire Upper Airway Stimulation System$122
- LIBTAYO$122
How this compares
$269,109 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Altamonte Springs
- Francisco CalimanoAltamonte Springs$1.3M
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.